Every material Form 8-K Quaker Chemical has filed with the SEC since February 24, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Quaker Chemical reported third-quarter 2026 results, with net sales of $544.5 million, up 10% from $493.8 million a year earlier, driven mainly by higher selling prices and new business wins. GAAP net income was $30.0 million, or $1.73 per diluted share, slightly below $30.5 million, or $1.75, in the prior-year quarter, while non-GAAP EPS rose to $2.39 from $2.08. Management expects fourth-quarter revenue and adjusted EBITDA to rise year over year but fall from the third-quarter level.
Net sales were $544.5 million, up 10% year over year; selling price and product mix contributed 7 points and sales volumes 3 points.
GAAP net income was $30.0 million, or $1.73 per diluted share, versus $30.5 million, or $1.75, in Q3 2025.
Non-GAAP EPS was $2.39 versus $2.08; adjusted EBITDA was $89.8 million, up about 8%.
For Q4 2026, management expects revenue and adjusted EBITDA to improve year over year but decline sequentially; it expects raw material costs to stay elevated through year-end.
Quaker Chemical appointed Neil Daniels as Vice President and Chief Accounting Officer, effective upon his anticipated start date of November 16, 2026, and he will serve as principal accounting officer. Thomas Coler, who has held that role since July 22, 2026, will step down from it and remain Executive Vice President and Chief Financial Officer.
Neil Daniels, age 61, appointed on October 16, 2026; start date November 16, 2026
Employment Agreement provides $370,000 annual base salary and a 2027 target incentive of 35% of base salary
Sign-on cash bonus of $175,000, plus long-term incentive grant with an aggregate value of $110,000
Thomas Coler ceases as principal accounting officer and continues as CFO
Quaker Chemical entered into an amendment to its credit agreement on October 1, 2026, creating a new $550 million seven-year term loan B facility. Proceeds will repay in full the U.S. Term Loans outstanding under the existing agreement, and the company said the deal extends its debt maturity profile and reduces required annual debt payments.
$550 million term loan B facility matures October 1, 2033
Interest at Term SOFR plus 1.750% for Term SOFR loans; quarterly amortization of 0.25% of initial principal
Proceeds repay in full the U.S. Term Loans; their aggregate principal balance is $0 as of the amendment's effective date
Facility is secured by first priority liens on substantially all assets and carries a 1.00% prepayment premium for a repricing event within six months
Quaker Chemical said Executive Vice President, Global Specialty and Chief Growth Officer Jeewat Bijlani will no longer serve in that role effective September 30, 2026. The company said the departure is not related to any disagreement and is treated as a termination without cause under his employment agreement, with severance subject to a customary release of claims.
Jeewat Bijlani's departure as Executive Vice President, Global Specialty and Chief Growth Officer is effective September 30, 2026
The company says the departure is not related to any disagreement with Bijlani
Separation is a termination without cause; severance is subject to a customary release of claims and follows the Company's March 31, 2026 proxy statement terms
Quaker Houghton reported second-quarter 2026 net sales of $532.6 million, up 10% from a year earlier, and net income of $26.8 million, or $1.55 per diluted share, compared with a net loss in the prior-year quarter that included $88.8 million of impairment charges. Management said it expects meaningful revenue and adjusted EBITDA growth in 2026 and announced a new $250 million share repurchase program.
Net sales of $532.6 million, up 10% year over year; sales volumes rose 7%
GAAP earnings of $1.55 per diluted share versus a loss of $3.78 a year earlier; non-GAAP EPS of $2.19 versus $1.71
Adjusted EBITDA of $85.2 million, up 13% year over year
New $250 million share repurchase program; no numeric 2026 guidance given, only expected meaningful growth in revenue and adjusted EBITDA
Quaker Houghton's Vice President, Corporate Controller and Principal Accounting Officer, Steven Dassing, resigned on June 30, 2026, effective July 22, 2026, to pursue another career opportunity, and the company says the resignation is not the result of any dispute. Executive Vice President and Chief Financial Officer Mr. Coler will also take on the Principal Accounting Officer role when Dassing's resignation takes effect, with no new compensatory arrangements.
Steven Dassing resigned as VP, Corporate Controller and Principal Accounting Officer on June 30, 2026, effective July 22, 2026
Dassing plans to pursue another career opportunity; the company states no dispute or disagreement was involved
CFO Mr. Coler, age 53, will serve as Principal Accounting Officer in addition to his CFO role
No new compensatory arrangements were entered into with Mr. Coler for the added role
Michael F. Barry, who had served as Quaker Chemical's chairman since 2009 and as a director since 2008, retired from the board effective at the close of the May 13, 2026 meeting, and Mark A. Douglas was appointed chairman that day. The board also cut its size from eleven to ten directors and eliminated the lead director role, while shareholders at the 2026 annual meeting elected three directors and approved the company's executive pay and its auditor, PricewaterhouseCoopers.
Michael F. Barry retired from the board, effective at the conclusion of the May 13, 2026 board meeting; the filing says the decision was voluntary and not due to any disagreement with the company.
Mark A. Douglas, a director since 2013, was appointed chairman on May 13, 2026, succeeding Barry.
The board reduced its size from eleven to ten directors and eliminated the Lead Director role, which Jeffry D. Frisby had held since 2023; Frisby remains on the board.
Shareholders elected Nandita Bakhshi, Joseph A. Berquist and Charlotte C. Henry to three-year terms ending at the 2029 annual meeting and ratified PricewaterhouseCoopers LLP for fiscal 2026.
Quaker Houghton reported first-quarter 2026 net sales of $480.5 million, up 8% from a year earlier, and net income attributable to the company of $19.7 million, or $1.13 per diluted share, compared with $0.73 in the first quarter of 2025. Management expects year-over-year revenue and adjusted EBITDA growth in 2026 if end markets do not deteriorate significantly, but says raw material inflation will temporarily weigh on second-quarter gross margins.
Net sales of $480.5 million, up 8%, with organic sales volumes up 3% and acquisitions contributing 4%
Net income of $19.7 million, or $1.13 per diluted share, vs $12.9 million, or $0.73, a year earlier; non-GAAP EPS of $1.63 vs $1.58
Adjusted EBITDA of $72.5 million, up 5%; the company's credit agreement was amended, extending its nearest maturity from June 2027 to April 2031
Global transformation and cost program targets $20 million to $30 million of annualized cost savings by 2028
Quaker Houghton signed Amendment No. 4 to its credit agreement on April 10, 2026, with Bank of America, N.A. as administrative agent. The new facilities include a $550 million U.S. dollar term loan, a $250 million euro-equivalent term loan and an $800 million revolving credit facility, which will repay the existing loans and replace the prior revolving commitments. The filing says the amendment extends the nearest debt maturity to 2031 and increases available credit, but the new debt is secured by first priority liens on substantially all company and guarantor assets and includes covenants that limit dividends and share repurchases.
Amended Credit Agreement signed April 10, 2026; all debt outstanding matures April 10, 2031
New facilities: $550 million U.S. dollar term loan, $250 million euro-equivalent term loan, $800 million revolving credit facility
Proceeds repay in full all outstanding loans under the existing credit agreement and terminate its revolving commitments
Debt is secured by first priority liens on substantially all assets of the Company and subsidiary guarantors
Quaker Chemical said Senior Vice President and Chief Global Operations Officer Jeffrey Fleck is no longer with the company, effective March 9, 2026. The filing describes the departure as an involuntary termination without cause and says it does not relate to any disagreement with the company.
Effective date of departure: March 9, 2026
Termination is involuntary and without cause under his January 23, 2023 employment agreement
Severance and benefits are subject to a customary release of claims and are consistent with those described in the March 31, 2025 proxy statement
Quaker Chemical reported fourth-quarter 2025 net sales of $468.5 million, up 6%, and net income of $20.7 million, or $1.18 per diluted share, versus $0.81 a year earlier. For the full year, the company posted a net loss of $2.5 million, or $0.14 per share, compared with net income of $116.6 million in 2024, after an $88.8 million impairment charge and $35.1 million of restructuring charges. Management expects end markets to remain at similar levels through the first half of 2026 and says it is confident in revenue and adjusted EBITDA growth in 2026, but the filing gives no numeric guidance.
Q4 2025 net sales were $468.5 million, up from $444.1 million; net income was $20.7 million, or $1.18 per diluted share, versus $0.81 a year earlier.
Full-year 2025 net loss of $2.5 million ($0.14 per diluted share) compared with net income of $116.6 million in 2024, including an $88.8 million impairment charge.
Q4 adjusted EBITDA rose 11% to $71.9 million; full-year non-GAAP EPS was $7.02 versus $7.44.
Operating cash flow was $136.5 million in 2025 versus $204.6 million in 2024; net debt was $691.4 million at December 31, 2025.
Quaker Chemical reported third-quarter 2025 net sales of $493.8 million, up 7% from a year earlier, driven by acquisitions, 3% organic volume growth and new business wins. GAAP net income and diluted earnings per share fell slightly from the prior year, while non-GAAP earnings per diluted share rose 10% to $2.08. Management expects year-over-year revenue and earnings growth in the fourth quarter, but said the soft operating environment will persist at least through year end.
Q3 2025 net sales were $493.8 million, up from $462.3 million in Q3 2024.
Q3 GAAP net income was $30.5 million, or $1.75 per diluted share, versus $32.3 million, or $1.81, a year earlier.
Non-GAAP earnings per diluted share were $2.08, compared with $1.89 in Q3 2024.
For the nine months ended September 30, 2025, the company reported a net loss of $23.2 million, including $88.8 million of impairment charges.
Quaker Houghton reported second-quarter 2025 net sales of $483.4 million, up 4% from a year earlier, but posted a net loss of $66.6 million, or $3.78 per diluted share, driven by an $88.8 million non-cash goodwill impairment tied to its EMEA segment. Non-GAAP earnings per diluted share fell to $1.71 from $2.13, and management expects a stronger second half with full-year 2025 revenue and earnings in the range of 2024.
Net sales rose 4% to $483.4 million from $463.6 million, with organic sales volumes up 2%.
Net loss of $66.6 million, or $3.78 per diluted share, compared with net income of $34.9 million a year earlier.
Non-GAAP earnings per diluted share were $1.71 versus $2.13; adjusted EBITDA was $75.5 million, down about 10%.
Management expects full-year 2025 revenue and earnings in the range of 2024 and about $20 million of run-rate cost savings by the end of 2026.
Quaker Chemical said Chief Accounting Officer Jeffrey Kutz resigned effective July 18, 2025, in a voluntary departure not tied to any disagreement with the company. Vice President and Corporate Controller Steve Dassing will also serve as Principal Accounting Officer, with his base salary set at $300,000 effective July 20, 2025.
Jeffrey Kutz resigned as Vice President, Chief Accounting Officer effective July 18, 2025; the filing says the departure was voluntary and not related to any disagreement.
Steve Dassing, age 39, will serve as Principal Accounting Officer in addition to his role as Vice President, Corporate Controller, which he has held since July 2024.
Dassing's base salary was set at $300,000 per year; his 2025 AIP target is 35% of base salary, and his long-term incentive target value is $110,000.
Quaker Chemical said director Ramaswami Seshasayee retired from its Board of Directors effective May 14, 2025, in a voluntary decision not tied to any disagreement with the company. The Board size was reduced from twelve to eleven directors, effective immediately. The filing describes a routine board change and does not mention any financial results or outlook.
Ramaswami Seshasayee retired from the Board effective May 14, 2025.
He had served on the Board since 2019 and sat on the Audit and Compensation and Human Resources Committees.
Board size reduced from twelve to eleven directors, effective immediately.
The filing states the retirement was voluntary and not due to any disagreement with the company.
Quaker Houghton reported first-quarter 2025 net sales of $442.9 million, down about 6% from $469.8 million a year earlier, and net income of $12.9 million, or $0.73 per diluted share, versus $35.2 million, or $1.95, in the prior-year quarter. Management said it expects revenue and earnings in 2025 to be in line with 2024, citing ongoing weak end-market demand and tariff uncertainty.
Net sales were $442.9 million, down about 6% from $469.8 million, with sales volumes down 3%.
Net income was $12.9 million, or $0.73 per diluted share, versus $35.2 million, or $1.95; non-GAAP earnings per diluted share were $1.58 versus $2.09.
Adjusted EBITDA was $69.0 million, down 17% from $83.3 million, and net cash used by operating activities was $3.1 million versus $27.2 million provided a year earlier.
The company acquired Dipsol Chemicals for about $155.2 million in April 2025, funded with borrowings under its existing credit facility.
Quaker Houghton reported fourth quarter and full year 2024 results on February 24, 2025. Q4 net sales fell 5% to $444.1 million and diluted EPS fell to $0.81 from $1.12, while full year net income rose to $116.6 million and diluted EPS rose to $6.51 from $6.26, even though full year net sales declined to $1.84 billion from $1.95 billion.
Q4 2024 net sales were $444.1 million, down from $467.1 million in Q4 2023; Q4 net income was $14.2 million, or $0.81 per diluted share, versus $20.2 million, or $1.12, a year earlier
Q4 adjusted EBITDA was $64.8 million, down about 16% from $77.0 million, driven by lower sales and operating margins
Full year 2024 net income was $116.6 million, or $6.51 per diluted share, compared with $112.7 million, or $6.26, in 2023; full year net sales were $1.84 billion versus $1.95 billion
The company expects run-rate cost savings of at least $20 million in 2025 and said it expects revenue, adjusted EBITDA and earnings growth in 2025, but did not provide formal GAAP guidance
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Quaker Chemical filing is on SEC EDGAR ↗. 8-K briefs of other companies →